Latest news for ASICS (OTC:ASCCY) Stock

Founded in 1949 in Kobe, Japan, Asics is a leading sports footwear brand specializing in performance running shoes. Asics is well-known for its stability running shoe Gel-Kayano, which has been popular among runners for over 30 years thanks to its cushioning technology. It also owns Onitsuka Tiger, which is a sports fashion brand named after the company's founder, Kihachiro Onitsuka. In 2023, Asics had annual sales of over JPY 570 billion, and it operated around 600 self-owned retail stores around the globe.

News

Legal

Sports

Interview

General

ADDYY

ASCCY

PMMAF

Sketchy: Industry Expert Says Latest Skechers-Adidas Litigation A &#39;PR Move&#39;

ASICS Corp

Barclays analyst Lauren Lieberman maintains Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Overweight and lowers the price target from $87 to $69.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Lamb Weston Hldgs, Lowers Price Target to $69

Lennox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), a leading provider of innovative climate control solutions, announced today its inclusion in the S&amp;P 500 Index, effective prior to the opening of trading. This milestone recognizes the company's sustained growth, innovation, and dedication to delivering advanced HVACR products that prioritize comfort and efficiency.
Widely recognized as the best single gauge of the U.S. large-cap market, the S&amp;P 500 measures the performance of 500 of the leading companies spanning all sectors of the U.S stock market. Inclusion in the index is determined by factors such as market capitalization, financial performance, and overall contribution to the economy, underscoring the success of Lennox in delivering value to shareholders and driving innovation.

Lennox Joins S&P 500, Highlighting Growth and Innovation in HVACR

Piper Sandler analyst Frank Schiraldi maintains Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) with a Overweight and raises the price target from $61 to $64.

TBBK

Piper Sandler Maintains Overweight on Bancorp, Raises Price Target to $64

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year.

Earnings

Earnings Beats

AVXL

Anavex Life Sciences Q4 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate; Cash Of $132.2M

VYNE Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive results from the multiple ascending dose ("MAD") portion of its Phase 1a SAD/MAD trial of VYN202. The Phase 1a trial was a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of single ascending dose ("SAD") and MAD components to evaluate the safety, tolerability, pharmacokinetics ("PK") and pharmacodynamics of VYN202.
Key Findings from the Top-line Phase 1a MAD Results for VYN202:
<ul>
<li>VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective bromodomain and extra-terminal domain ("BET") inhibitors, including thrombocytopenia, neutropenia or gastrointestinal toxicity findings
<ul>
<li>No serious adverse events (AEs), discontinuations due to an AE or clinically meaningful treatment emergent adverse events (TEAEs). All TEAEs were considered mild or moderate in severity.</li>
<li>No drug-related adverse events associated with laboratory results. There were no AEs of any severity grade relating to thrombocytopenia, which is a known dose-limiting toxicity associated with earlier generations of BET inhibitors. &nbsp;</li>
</ul>
</li>
<li>Favorable PK profile demonstrated for VYN202: 
<ul>
<li>Data supports once-daily dosing regimen.</li>
<li>VYN202 demonstrated dose dependent exposure that reached steady-state after 7 once-daily doses.</li>
<li>VYN202 blood levels were within key inhibitory thresholds of IC50 to IC90 against BD2 BRD4 for at least 24 hours at all doses.</li>
<li>No drug-drug interaction was observed when VYN202 was co-administered with methotrexate, a treatment commonly used in the management of chronic immuno-inflammatory conditions. &nbsp;</li>
</ul>
</li>
<li>VYN202 demonstrated robust pharmacodynamic activity on target engagement and inflammatory biomarkers in ex vivo assays: 
<ul>
<li>VYN202 induced a dose-dependent increase in the target engagement biomarker HEXIM-11 with a maximal effect observed at 0.5mg to 1.0 mg QD.</li>
<li>VYN202 inhibited the production of multiple inflammatory biomarkers related to Th17, Th1/myeloid and Th1/Tc dysregulated activity, consistent with preclinical models of VYN202.</li>
</ul>
</li>
</ul>

VYNE

VYNE Therapeutics Reports Results from Phase 1a Trial of VYN202

Barclays analyst Andrew Lazar maintains Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Overweight and lowers the price target from $33 to $32.

Barclays Maintains Overweight on Conagra Brands, Lowers Price Target to $32

Piper Sandler analyst Crispin Love maintains SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) with a Neutral and raises the price target from $77 to $87.

SEIC

Piper Sandler Maintains Neutral on SEI Inv, Raises Price Target to $87

Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that the Company successfully integrated Meshy 4 into their artificial intelligence solution for game developers and publishers, Gaxos Labs.
The Meshy 4 update and integration allows artists, designers, and developers to fine-tune mesh topology, limit polycounts, and produce higher-quality 3D models faster and in a more efficient workflow. By utilizing Meshy 4's advanced generative geometry, users can seamlessly toggle between quad- or triangle-based meshes to suit the specific demands of their project. This freedom allows creators to tailor 3D assets to their exact needs—whether it's smoother surfaces for characters and animations or intricate details for complex environments. The new polycount limitation feature keeps assets from becoming resource-intensive, ensuring smoother performance and simple integration with real-time engines.

GXAI

Gaxos Enhances Game Development with Meshy 4 Integration in AI Platform

Berkshire Hathaway Chairman Warren Buffett may have had some rather sharp things to say about cryptocurrency as an asset class, but that didn't deter the veteran Wall Street investor from engaging with some of the biggest names in the industry. 
What happened: Cryptocurrency mogul and founder of Tron (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/trx/usd">TRX</a>) blockchain Justin Sun has been known for his<a href="https://www.benzinga.com/24/11/42253045/62m-duct-taped-banana-becomes-a-snack-as-crypto-mogul-justin-sun-asserts-this-conceptual-artwork-can-be-assembled-and-disassembled-anywhere"> flamboyant opulence</a>, spending millions to win bids that signal his status.
Back in 2019, Sun won the eBay charity auction to have lunch with Buffett with a record-setting $4.57 million bid. He finally <a href="https://www.benzinga.com/markets/cryptocurrency/20/02/15270316/bittorrent-ceo-justin-suns-4-5-million-dinner-with-warren-buffett">had his date</a> with the "Oracle of Omaha&#8221; on Feb. 6, 2020, bringing with him other big industry entrepreneurs like Litecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>) creator Charlie Lee.
At the time, Tron's native cryptocurrency, TRX, was priced at $0.022633. So, an investment of $1000 would have fetched you 44,183.272 units of the asset.
Cut to Dec. 2024, one TRX is valued at $0.2465. So, if you HODLed your way through the ebb and flow of the market, your stash would be worth $10,891 today, netting a massive 989% return.
See Also: <a href="https://www.benzinga.com/24/12/42640293/trump-congratulates-bitcoiners-on-new-all-time-highs-as-apex-crypto-suffers-first-weekly-loss-since-election-triumph">Trump Congratulates Bitcoin Community On New All-Time Highs Just As Top Crypto Suffers First Weekly Loss Since His Election Triumph</a>
Why It Matters: When Sun won the lunch with Buffett, he penned an open <a href="https://trondao.medium.com/an-open-letter-to-the-community-warren-buffett-charity-lunch-8c5bf25d4fe8">letter </a>saying that he would have a conversation with the Wall Street legend on cryptocurrencies and blockchain.&nbsp;
"I want to point out, though, that even one of the most successful investors of all times can sometimes miss a coming wave," Sun wrote, but admitted that even the blockchain community has a "lot to prove" about the benefits of the industry.
While we don't know what transpired between Sun and Buffett on that day, one thing is certain. The Berkshire Hathaway Chair's <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42184221/warren-buffett-once-predicted-a-bad-ending-for-crypto-since-then-the-sectors-market-cap-has-quadrupled-riding-on-the-bitcoin-dogecoin-waves">views on cryptocurrencies</a> haven't changed much.
Price Action: At the time of writing, TRX was exchanging hands at $0.2465, up 0.33 % in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Image via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42640482/dogecoin-flips-into-the-green-as-trump-appoints-longtime-loyalist-katie-miller-to-join-the-department-of-government-efficiency">Dogecoin Turns Green As Trump Appoints Loyalist Katie Miller To The Department Of Government Efficiency</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$LTC

$TRX

If You Invested $1000 In This Ethereum Killer When Warren Buffett Had Dinner With Justin Sun, Here's How Much You'd Have Today

Piper Sandler analyst Crispin Love maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Overweight and raises the price target from $25 to $27.

Piper Sandler Maintains Overweight on Blue Owl Cap, Raises Price Target to $27

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for blarcamesine (ANAVEX&#xAE;2-73), an investigational drug for the treatment of Alzheimer's disease. The Company is looking forward to working with the EMA.
Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer's disease.

Government

Regulations

Anavex's Alzheimer's Drug Blarcamesine Accepted for Review by European Regulators

Piper Sandler analyst Sumeet Mody maintains Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) with a Neutral and raises the price target from $10 to $11.5.

ENFN

Piper Sandler Maintains Neutral on Enfusion, Raises Price Target to $11.5

Barclays analyst Brandt Montour maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Overweight and raises the price target from $31 to $32.

Barclays Maintains Overweight on Carnival, Raises Price Target to $32

Institutional adoption of cryptocurrencies is now &#8220;for real this time,&#8221; according to Messari's 2025 crypto theses report, which highlights the growing presence of traditional finance <a href="https://www.benzinga.com/24/12/42516240/the-doors-have-been-blown-off-how-bitcoin-etfs-are-reshaping-investment-strategies">in digital assets</a>.
What Happened: The <a href="https://messari.io/report/the-crypto-theses-2025">report</a> cites approvals of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42526592/bitcoin-ethereum-etfs-see-688m-net-inflows-analysts-target-124000">exchange-traded funds</a> (ETFs), increasing involvement from major financial players and the expanding role of tokenized assets as evidence that institutional adoption is firmly underway.
Messari emphasizes that institutional engagement has shifted beyond ETFs, with asset issuance, <a href="https://www.benzinga.com/money/how-do-stablecoins-make-money">stablecoin development</a> and broader <a href="https://www.benzinga.com/money/what-is-blockchain">blockchain applications</a> gaining momentum.
&#8220;The institutions are here &#8211; this time for real. The approval of the BTC and ETH ETFs has legitimized the asset class and made it more accessible to both retail and institutional allocators,&#8221; the report states.
The report also highlights other key developments reshaping the crypto industry, including the rise of <a href="https://www.benzinga.com/money/depin-crypto-coins">decentralized physical infrastructure networks (DePIN)</a>, which saw significant growth in sectors like compute, energy and mobility.
The market capitalization of DePIN projects surged by 132% year-over-year, showcasing their role in bridging blockchain infrastructure with real-world applications.
Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) emerged as another standout performer, achieving notable gains in 2024 driven by advancements like the Firedancer upgrade and its dominance in decentralized exchange volumes. 
Messari points to Solana's ability to deliver high throughput and lower costs, positioning it as a growing competitor to Ethereum.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42526592/bitcoin-ethereum-etfs-see-688m-net-inflows-analysts-target-124000">Bitcoin, Ethereum ETFs See $688M Net Inflows, Analysts Target $124,000</a>
Meanwhile, Ethereum continues to play a central role as Layer-2 scaling solutions gain traction, improving network efficiency and throughput. 
The report notes that while Ethereum remains foundational, Layer-2 rollups have outpaced Layer-1 activity, reflecting the platform's evolving role amid market competition.
Messari also explores the expanding Bitcoin ecosystem, where institutional inflows and increasing utility are bolstering Bitcoin&#8217;s recognition as a macroeconomic hedge. 
The convergence of <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42512673/ai-cryptocurrencies-surge-208-to-61-5-billion-market-cap-in-2024-these-were-the-top-perfor">AI and crypto</a> is another trend identified in the report, with decentralized AI projects like Bittensor (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>) driving innovation and enabling new use cases for blockchain technology.
The report further highlights renewed innovation across DeFi, stablecoins,and consumer apps, reflecting broader momentum in the crypto market.
What&#8217;s Next: With institutional participation now firmly entrenched and multiple sectors experiencing growth, Messari concludes that the macro environment for crypto adoption has entered a new phase.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42514820/ftx-reorganization-plan-set-for-january-3-distributions-to-commence-within-60-days">FTX Reorganization Plan Set For January 3, Distributions To Commence Within 60 Days</a></li>
</ul>
Image: Shutterstock

$BTC

$ETH

$SOL

$TAO

Institutional Crypto Adoption 'For Real This Time,' Says Messari

Piper Sandler analyst Crispin Love upgrades GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raises the price target from $12.5 to $14.

Upgrades

GCMG

Piper Sandler Upgrades GCM Grosvenor to Overweight, Raises Price Target to $14

ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "Company or "ParaZero"), an aerospace company focused on safety systems for defense and commercial drones and urban air mobility aircrafts, previously announced that it received an order for its SafeAir&#x2122; systems from a significant distributor specializing in drones and drone technology in Australia.&nbsp;
This order, which was announced earlier this month, highlights ParaZero's accelerating growth in the Australian drone market, fuelled by its recent regulatory approvals and strategic collaborations. As the adoption of drones expands across industries, ParaZero's cutting-edge solutions reflect its commitment to set and advance the standards for drone safety, empowering operators to meet the highest safety standards while advancing innovation.
ParaZero's SafeAir&#x2122; systems are designed to autonomously detect flight anomalies and deploy a parachute, minimizing risks and ensuring safety in complex drone operations. <a href="https://www.globenewswire.com/Tracker?data=QoObMc4XRrrTqiWs0k8_qO33cD3CMq0UvGwl51vxxlcF0mDpN2lA2yia9Fg0kzzpjkjtx1ULSLRYg97m8BnoM-_KDkr4C8FWkZnJ0Fo3Afe3QEEy2MHQUSaCmJnu3vIMQMHgQFX8s1gLOrA0JfZutc7InXJYaM_AO6MjXTLDTCKYJW4TC4Bjnou7wDXqyJGb8dfAL2ReLtF64U7q5b6NNdmvIV4K2OEdeapaOF01ry-A9DGJuCO-24Ym2SJs3vsi4OcFF__8Zd9f4EyU4oqgI70ATWS2jrfZ-ZA01LLIaFO0_iBRsHhMiMMYuGqIxpskYlgg8298TCuoKcTU_MF0ZeyZ_67jPSjMQob_TkkXxzL3giAM1je56cBK7o2c_l1ukdziVbHhM1RL5CHnB-R_LjvqhuTfPXlQPdJ64UMkEHygwebuUrfv5AeqwVpnZCSw">In October 2023, ParaZero's technology received approval from the Civil Aviation Safety Authority (CASA),</a> enabling commercial drone flights over populated areas and near people—a landmark regulatory milestone in Australia.
Collaborating with prominent local distributors has been central to ParaZero's success in the region. By leveraging these partnerships, ParaZero has made its CASA-approved safety systems widely accessible, empowering operators to conduct advanced and safe drone missions.

PRZO

ParaZero Expands Australian Market with Drone Safety Tech Order

TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) ("TeraWulf" or the "Company"), a leading owner and operator of vertically integrated, next-generation digital infrastructure powered by predominantly zero-carbon energy, today announced the signing of long-term data center lease agreements with Core42, a G42 company specializing in sovereign cloud, AI infrastructure, and digital services.
Under the data center lease agreements, TeraWulf will deliver over 70 megawatts (MW)1 of turn-key data center infrastructure to host Core42's deployment at the Lake Mariner facility in Upstate New York. The infrastructure will be released for production in phases between Q1 and Q3 2025.
TeraWulf will customize the data halls to support Core42's GPU clusters, which will feature state-of-the-art Dell Integrated Rack Scalable Solutions, the <a href="https://www.globenewswire.com/Tracker?data=8y3F9NNOZ4U380vPkbI8fe67XMhPiVwXtKFjU9eKri1zk3MMWLeb-6czzf0hIjok1UMddGJxZKnvd5PmTGKCS1iap9rsJ6TlsURqvPDiEUIoX3gfCHBlldx0d4Es1MDcS6en9sCc4MuJoo2v55gc5W53FbkTyYxZ9S5xyyVC8lQcGF0H986d-yCxlkPIAhXl">Dell IR5000</a>. These integrated racks include direct liquid cooled Dell PowerEdge XE9680L GPU servers and will come online in phases.

WULF

TeraWulf Partners with Core42 to Provide 70 MW Data Center for AI Infrastructure

HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) ("HUB" or the "Company"), a leader in cybersecurity and advanced data fabric solutions, has successfully restructured $7 million of its secured debt with United Mizrahi Tefahot Bank ("UMTB") under a settlement agreement signed on December 19, 2024 between HUB and UMTB (the "Agreement"). The Agreement represents over 60% of HUB's secured debt, through its wholly-owned subsidiary Comsec Ltd., and reflects the Company's commitment to address key financial obligations in its ongoing efforts to settle or extend most of its outstanding debt to achieve financial stability and confidence in its growth trajectory.
Under the Agreement, payments are deferred until June 2025, aligning with HUB's expected free cash flow generation. This milestone enhances liquidity and enables the Company to focus on scaling operations and delivering shareholder value. Furthermore, HUB is in advanced negotiations to refinance the remainder of its secured debt, with completion expected in the first quarter of 2025.

HUBC

HUB Cyber Security Restructures $7M Debt to Boost Financial Stability

<a href="https://www.ft.com/content/77bd9117-0a2d-4bd7-9248-4dd288f695a4" title="https://www.ft.com/content/77bd9117-0a2d-4bd7-9248-4dd288f695a4">https://www.ft.com/content/77bd9117-0a2d-4bd7-9248-4dd288f695a4</a>

Fintech news covering the emerging Financial Technology services sector

Fintech

Rumors

Financial Times Reported Meta Plans To Add Displays To Its Ray-ban Smart Glasses As Soon As Next Year

Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary data from the Company's ongoing prospective development and validation study, Castle's pipeline test has shown potential to identify a subset of patients with AD who have an increased likelihood to achieve a super response to targeted therapies, indicated by a 90% or greater reduction in Eczema Area and Severity Index (EASI) score (EASI90) at three months. Assuming successful validation, the Company currently expects to launch its pipeline test by the end of 2025.

Comments

ASICS

News

Latest news for ASICS (OTC:ASCCY) Stock

Tuesday, March 24, 2020

Friday, May 18, 2018

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga